DAFTAR PUSTAKA

1. Ayuningtyas D, Yolanda E, Evaluasi P, Kebijakan I, Ayuningtyas D, Panggabean EY, et al. Evaluasi Implementasi Kebijakan Kewajiban Menuliskan Resep Obat Generik Di Rumah Sakit Umum Cilegon Tahun 2007. J Manaj Pelayanan Kesehat. 2010;13(04):198–205.
2. Sitindaon HS. Gambaran tingkat pengetahuan masyarakat tentang obat generik di Kecamatan Medan Sunggal Kelurahan Babura Medan tahun 2010. Universitas Sumatera Utara; 2011.
3. Waber RL, Shiv B, Carmon Z, Ariely D. Commercial Features of Placebo and Therapeutic Efficacy. J Am Med Assoc. 2008;299(9):1016–7.
4. Colloca L. Nocebo effects can make you feel pain. Science (80-). 2017;358(6359):44.
5. Fahriani AA. Hubungan Antara Persepsi Pasien Terhadap Obat Generik dengan Pengalaman Kesembuhan, Kepuasan, dan Kunjungan Kembali. Indones Public Heal Student J. 2014;
6. Kesselheim AS, Gagne JJ, Franklin JM, Eddings W, Fulchino LA, Avorn J, et al. Variations in Patient's Perceptions and Use of Generic Drugs: Results of a National Survey. J Gen Intern Med. 2016;31(6):609–14.
7. Kesselheim AS, Gagne JJ, Eddings W, Franklin JM, Ross KM, Fulchino LA, et al. Prevalence and predictors of generic drug skepticism among physicians: Results of a national survey. JAMA Intern Med. 2016;176(6):845–7.
8. Sarpatwari A, Kesselheim AS. The Case for Reforming Drug Naming: Should Brand Name Trademark Protections Expire upon Generic Entry? PLoS Med. 2016;13(2):1–6.
9. Badan Pengawas Obat dan Makanan. Peraturan Kepala Badan Pengawas Obat Dan Makanan Republik Indonesia NO: HK .00.05.3.1818 Tentang Pedoman Uji Bioekivalensi. 2004.
10. Sweetman SC. Martindale: The Complete Drug Reference. 36th ed. London: Pharmaceutical Press; 2009.
11. Kementrian Kesehatan Republik Indonesia. Keputusan Menteri Kesehatan Republik Indonesia Nomor HK.01.07/Menkes/395/2017 Tentang Daftar Obat Esensial Nasional. 2017. p. 1–48.
12. Nasif H, Zaini E, Agnes S. Uji Dissolusi Terbanding Tablet Metilprednisolon Generik Bermerek dan Generik Berlogo Dibandingkan Dengan Tablet Metilprednisolon Paten. J Sains dan Teknol Farm. 2017;19(Desember):46–51.
13. Prasanthi NL, Sudhir M, Jyothi N, Sri V. A Review on Polymorphism Perpetuates Pharmaceuticals. Am J Adv Drug Deliv. 2016;4(5):58–63.
14. Raza K, Kumar P, Ratan S, Malik R, Arora S. Polymorphism: The Phenomenon Affecting the Performance of Drugs. SOJ Pharm Pharm Sci. 2014;1(2).
15. Li Y, Chow PS, Tan RBH. Quantification of polymorphic impurity in an

enantiotropic polymorph system using differential scanning calorimetry, X-ray powder diffraction and Raman spectroscopy. Int J Pharm. 2011;415(1–2):110–8.
16. van Eupen JTH, Westheim R, Deij MA, Meekes H, Bennema P, Vlieg E. The solubility behaviour and thermodynamic relations of the three forms of Venlafaxine free base. Int J Pharm. 2009;368(1–2):146–53.
17. Higuchi WI, Lau PK, Higuchi T, Shell JW. Polymorphism and Drug Availability; Solubility Relationships in the Methylprednisolone System. J Pharm Sci. 1963;52:150–3.
18. Levy G, Procknal JA. Dissolution rate studies on methylprednisolone polymorphs. J Pharm Sci. 1964;53(6):656–8.
19. Nasif H, Lucida H, Yanwirasti Y, Aldi Y, Yuliandra Y. Pharmacodynamics Effect of Methylprednisolone Tablets on the Serum Concentration of Annexin A1: in Vivo Comparative Study Between Generic and Innovator Drug. Asian J Pharm Clin Res. 2019;12(1):414–7.
20. Kementrian Kesehatan Republik Indonesia. Peraturan Menteri Kesehatan Republik Indonesia Nomor 74 Tahun 2016 Tentang Standar Pelayanan Kefarmasian di Puskesmas. 2016.
21. Katzung BG, Masters SB, Trevor AJ. Basic & Clinical Pharmacology. Twelfth Ed. New York: McGraw-Hill Education; 2012.
22. Shargel L, Yu ABC. Applied Biopharmaceutics & Pharmacokinetics. Seventh Ed. New York: McGraw-Hill Education; 2016.
23. Nuryati. Farmakologi. Jakarta Selatan: Kementerian Kesehatan Republik Indonesia; 2017. 266 p.
24. Kementrian Kesehatan Republik Indonesia. Permenkes RI NO. HK.02.02/MENKES/068/I/2010 Tentang Kewajiban Menggunakan Obat Generik di Fasilitas Kesehatan Pemerintah. 2010.
25. UU No 13 Tahun 2016 Tentang Paten. In: UU NO 13 2016 Tentang Paten. 2016. p. 1–86.
26. Tan HT, Rahardja K. Obat-Obat Penting Kasiat, Penggunaan dan Efek-Efek Sampingnya. Edisi Keen. Jakarta: PT Elex Media Komputindo; 2007.
27. Dunne S, Shannon B, Dunne C, Cullen W. A review of the differences and similarities between generic drugs and their originator counterparts, including economic benefits associated with usage of generic medicines, using Ireland as a case study. BMC Pharmacol Toxicol. 2013;14:1–19.
28. Khoiruzzad Z. Profil Penggunaan Obat Generik Berlogo dan Obat Generik Bermerek (Branded Generic) Anti Diabetik Oral di Instalasi Rawat Inap Rumah Sakit Umum Daerah Dr. Moewardi Surakarta Tahun 2009. Universitas Muhammadiyah Surakarta; 2010.
29. Hansen RA, Qian J, Berg R, Linneman J, Seoane-Vazquez E, Dutcher SK, et al. Comparison of Generic-to-Brand Switchback Patterns for Generic and Authorized Generic Drugs. Pharmacotherapy. 2017;37(4):429–37.
30. Simoens S. International comparison of generic medicine prices. Curr Med Res Opin. 2007;23(11):2647–54.
31. Strauss J, Greeff O. Excipient-Related Adverse Drug Reactions: A Clinical Approach. Curr Allergy Clin Immunol. 2014;28(1).

32. Mumoli N, Cei M, Luschi R, Carmignani G, Camaiti A. Allergic Reaction to Croscarmellose Sodium Used as Excipient of a Generic Drug. QJM - Mon J Assoc Physicians. 2011;104(8):709–10.
33. Loyd V. Allen J, Popovich NG, Ansel HC. Ansel's Pharmaceutical: Dosage Forms and Drug Delivery Systems. ninth edit. Philadelphia: Lippincott Williams & Wilkins; 2011.
34. Lieberman HA, Lachman L, Schwartz JB. Pharmaceutical Dosage Forms: Tablets. Vol. 1. Second Edi. Vol. 79, Journal of Pharmaceutical Sciences. New York: MARCEL DEKKER. INC.; 1989.
35. Kementrian Kesehatan Republik Indonesia. Farmakope Indonesia. Edisi III. Jakarta: Departemen Kesehatan RI; 1979.
36. U.S Pharmacopeia. The United States Pharmacopeia, USP 32/The National Formulary, NF 27. Rockville, MD: U.S. Phamacopeiaa Convention, Inc; 2007.
37. McEvoy GK. AHFS Drug Information Essentials. Bethesda: American Society of Health-System Pharmacists; 2011.
38. Committee JF. British National Formulary. 69th ed. London: BMJ Group and the Royal Pharmaceutical Society; 2015.
39. Kementrian Kesehatan Republik Indonesia. Farmakope Indonesia. Edisi V. Jakarta: Departemen Kesehatan RI; 2014.
40. Censi R, Di Martino P. Polymorph impact on the bioavailability and stability of poorly soluble drugs. Molecules. 2015;20(10):18759–76.
41. Attwood D, Florence AT. Physical Pharmacy. London: Pharmaceutical Press; 2008.
42. Sinko PJ. Martin's Physical Pharmacy And Pharmaceutical Sciences: Physical Chemical and Biopharmaceutical Principles in the Pharmaceutical Sciences. sixth edit. Philadelphia: Lippincott Williams & Wilkins; 2011.
43. HG B. Polymorphism in Pharmaceutical Solids. Second Edi. New York: Informa Healthcare Inc.; 2009.
44. Llinàs A, Goodman JM. Polymorph Control: Past, Present and Future. Drug Discov Today. 2008;13(5–6):198–210.
45. Setiabudi A, Hardian R, Mudzakir A. Karakterisasi Material; Prinsip dan Aplikasinya dalam Penelitian Kimia. Bandung: UPI Press; 2012.
46. Masrukan. Analisis Kualitatif dengan Menggunakan Teknik Difraksi Sinar-X pada Penambahan Unsur Zr tehadap Pembentukan Fasa Paduan U-Zr. 2008;14(2):65–76.
47. Swarjana IK. Metodologi Penelitian Kesehatan. Yogyakarta: Penerbit ANDI; 2012.
48. Jafari-Aghdam N, Adibkia K, Payab S, Barzegar-Jalali M, Parvizpur A, Mohammadi G. Methylprednisolone acetate – Eudragit® RS100 Electrospuns : Preparation and Physicochemical Characterization. 2014;98(August):1–7.
49. Kumar D, Singh J, Antil M, Kumar V. Quality Control Of Tablets: A Review. Int J Univers Pharm Bio Sci. 2016;5(4):53–67.
50. Suryanarayana C, Norton MG. X-Ray Diffraction: A Practical Approach. Handbook of Nanomaterials for Hydrogen Storage. New York: Springer

Science+Business Media, LLC; 1998.
51. Setianingsih T, Sutarno. Prinsip Dasar dan Aplikasi Metode Difraksi Sinar-X untuk Karakterisasi Material. Malang: UB Press; 2018.